Mechanisms behind efficacy of tumor necrosis factor inhibitors in inflammatory bowel diseases

Pharmacology and Therapeutics

Volumn 159, Issue , 2016, Pages 110-119

  Olesen, Caroline Meyer ^a   Coskun, Mehmet ^a   Peyrin Biroulet, Laurent ^b   Nielsen, Ole Haagen ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY HOSPITAL OF NANCY   (France)

Author keywords

Crohn's disease; IBD; Inflammatory pathways; TNF inhibitors; Ulcerative colitis

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; GOLIMUMAB; INFLIXIMAB; TUMOR NECROSIS FACTOR INHIBITOR; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; COMPLEMENT DEPENDENT CYTOTOXICITY; CROHN DISEASE; DRUG BINDING; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; GASTRIC MUCOSA; HEALING; HUMAN; INFLAMMATORY BOWEL DISEASE; INFORMATION RETRIEVAL; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; TREATMENT RESPONSE; ULCERATIVE COLITIS; ANTAGONISTS AND INHIBITORS; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASES; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; HUMANS; INFLAMMATORY BOWEL DISEASES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84959543785     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2016.01.001     Document Type: Review

References (116)

1. J. Agnholt, and K. Kaltoft Infliximab downregulates interferon-gamma production in activated gut T-lymphocytes from patients with Crohn's disease Cytokine 15 2001 212 222
2. J. Agnholt, J. Kelsen, B. Brandsborg, N.O. Jakobsen, and J.F. Dahlerup Increased production of granulocyte-macrophage colony-stimulating factor in Crohn's disease - a possible target for infliximab treatment Eur J Gastroenterol Hepatol 16 2004 649 655
3. S.H. Ahn, Y.M. Shah, J. Inoue, K. Morimura, I. Kim, S. Yim, and et al. Hepatocyte nuclear factor 4alpha in the intestinal epithelial cells protects against inflammatory bowel disease Inflamm Bowel Dis 14 2008 908 920
4. I. Arijs, G. De Hertogh, K. Machiels, K. Van Steen, K. Lemaire, A. Schraenen, and et al. Mucosal gene expression of cell adhesion molecules, chemokines, and chemokine receptors in patients with inflammatory bowel disease before and after infliximab treatment Am J Gastroenterol 106 2011 748 761
5. A. Armuzzi, P. Lionetti, C. Blandizzi, R. Caporali, S. Chimenti, L. Cimino, and et al. Anti-TNF agents as therapeutic choice in immune-mediated inflammatory diseases: focus on adalimumab Int J Immunopathol Pharmacol 27 2014 11 32
6. T. Arora, R. Padaki, L. Liu, A.E. Hamburger, A.R. Ellison, S.R. Stevens, and et al. Differences in binding and effector functions between classes of TNF antagonists Cytokine 45 2009 124 131
7. R. Atreya, M. Zimmer, B. Bartsch, M.J. Waldner, I. Atreya, H. Neumann, and et al. Antibodies against tumor necrosis factor (TNF) induce T-cell apoptosis in patients with inflammatory bowel diseases via TNF receptor 2 and intestinal CD14(+) macrophages Gastroenterology 141 2011 2026 2038
8. J. Barsig, S. Kusters, K. Vogt, H.D. Volk, G. Tiegs, and A. Wendel Lipopolysaccharide-induced interleukin-10 in mice: role of endogenous tumor necrosis factor-alpha Eur J Immunol 25 1995 2888 2893
9. M. Benucci, G. Saviola, M. Manfredi, P. Sarzi-Puttini, and F. Atzeni Tumor necrosis factors blocking agents: analogies and differences Acta Biomed 83 2012 72 80
10. P. Biancheri, R.J. Brezski, A. Di Sabatino, A.R. Greenplate, K.L. Soring, G.R. Corazza, and et al. Proteolytic cleavage and loss of function of biologic agents that neutralize tumor necrosis factor in the mucosa of patients with inflammatory bowel disease Gastroenterology 149 2015 1564 1574
11. T. Billiet, P. Rutgeerts, M. Ferrante, G. Van Assche, and S. Vermeire Targeting TNF-alpha for the treatment of inflammatory bowel disease Expert Opin Biol Ther 14 2014 75 101
12. C.G. Bjorkesten, U. Nieminen, T. Sipponen, U. Turunen, P. Arkkila, and M. Farkkila Mucosal healing at 3 months predicts long-term endoscopic remission in anti-TNF-treated luminal Crohn's disease Scand J Gastroenterol 48 2013 543 551
13. E.J. Breese, C.A. Michie, S.W. Nicholls, S.H. Murch, C.B. Williams, P. Domizio, and et al. Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease Gastroenterology 106 1994 1455 1466
14. S.J. Brown, and L. Mayer The immune response in inflammatory bowel disease Am J Gastroenterol 102 2007 2058 2069
15. G. Cammarota, G. Ianiro, R. Cianci, S. Bibbo, A. Gasbarrini, and D. Curro The involvement of gut microbiota in inflammatory bowel disease pathogenesis: potential for therapy Pharmacol Ther 149 2015 191 212
16. F. Caprioli, F. Bose, R.L. Rossi, L. Petti, C. Vigano, C. Ciafardini, and et al. Reduction of CD68+ macrophages and decreased IL-17 expression in intestinal mucosa of patients with inflammatory bowel disease strongly correlate with endoscopic response and mucosal healing following infliximab therapy Inflamm Bowel Dis 19 2013 729 739
17. W.M. Chu Tumor necrosis factor Cancer Lett 328 2013 222 225
18. J.F. Colombel, P. Rutgeerts, W. Reinisch, D. Esser, Y. Wang, Y. Lang, and et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis Gastroenterology 141 2011 1194 1201
19. P. Cordiali-Fei, L. Bianchi, C. Bonifati, E. Trento, M. Ruzzetti, F. Francesconi, and et al. Immunologic biomarkers for clinical and therapeutic management of psoriasis Mediators Inflamm 2014 2014 236060
20. M. Coskun Intestinal epithelium in inflammatory bowel disease Front Med (Lausanne) 1 2014 24
21. M. Coskun, and O.H. Nielsen Tumor necrosis factor inhibitors for inflammatory bowel disease N Engl J Med 369 2013 2561 2562
22. M. Coskun, A.K. Olsen, T.L. Holm, P.H. Kvist, O.H. Nielsen, L.B. Riis, and et al. TNF-alpha-induced down-regulation of CDX2 suppresses MEP1A expression in colitis Biochim Biophys Acta 1822 2012 843 851
23. S. Danese, M. Sans, F. Scaldaferri, A. Sgambato, S. Rutella, A. Cittadini, and et al. TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn's disease J Immunol 176 2006 2617 2624
24. M. de Bruyn, K. Machiels, J. Vandooren, B. Lemmens, L. Van Lommel, C. Breynaert, and et al. Infliximab restores the dysfunctional matrix remodeling protein and growth factor gene expression in patients with inflammatory bowel disease Inflamm Bowel Dis 20 2014 339 352
25. S. Derer, A. Till, R. Haesler, C. Sina, N. Grabe, S. Jung, and et al. mTNF reverse signalling induced by TNFalpha antagonists involves a GDF-1 dependent pathway: implications for Crohn's disease Gut 62 2013 376 386
26. G.R. D'Haens Top-down therapy for IBD: rationale and requisite evidence Nat Rev Gastroenterol Hepatol 7 2010 86 92
27. A. Di Sabatino, R. Ciccocioppo, B. Cinque, D. Millimaggi, R. Morera, L. Ricevuti, and et al. Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease Gut 53 2004 70 77
28. A. Di Sabatino, S.L. Pender, C.L. Jackson, J.D. Prothero, J.N. Gordon, L. Picariello, and et al. Functional modulation of Crohn's disease myofibroblasts by anti-tumor necrosis factor antibodies Gastroenterology 133 2007 137 149
29. A.U. Dignass Mechanisms and modulation of intestinal epithelial repair Inflamm Bowel Dis 7 2001 68 77
30. G. Dumitrescu, A. Amiot, P. Seksik, C. Baudry, C. Stefanescu, C. Gagniere, and et al. The outcome of infliximab dose doubling in 157 patients with ulcerative colitis after loss of response to infliximab Aliment Pharmacol Ther 42 2015 1192 1199
31. H.G. Evans, U. Roostalu, G.J. Walter, N.J. Gullick, K.S. Frederiksen, C.A. Roberts, and et al. TNF-alpha blockade induces IL-10 expression in human CD4+ T cells Nat Commun 5 2014 3199
32. A. Fischer, M. Gluth, U.F. Pape, B. Wiedenmann, F. Theuring, and D.C. Baumgart Adalimumab prevents barrier dysfunction and antagonizes distinct effects of TNF-alpha on tight junction proteins and signaling pathways in intestinal epithelial cells Am J Physiol Gastrointest Liver Physiol 304 2013 G970 G979
33. W. Fries, C. Muja, C. Crisafulli, S. Cuzzocrea, and E. Mazzon Dynamics of enterocyte tight junctions: effect of experimental colitis and two different anti-TNF strategies Am J Physiol Gastrointest Liver Physiol 294 2008 G938 G947
34. J.P. Gisbert, A.C. Marin, A.G. McNicholl, and M. Chaparro Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed Aliment Pharmacol Ther 41 2015 613 623
35. L. Guidi, C. Felice, A. Procoli, G. Bonanno, E. Martinelli, M. Marzo, and et al. FOXP3(+) T regulatory cell modifications in inflammatory bowel disease patients treated with anti-TNFalpha agents Biomed Res Int 2013 2013 286368
36. C. Gunther, H. Neumann, M.F. Neurath, and C. Becker Apoptosis, necrosis and necroptosis: cell death regulation in the intestinal epithelium Gut 62 2013 1062 1071
37. A.L. Hart, H.O. Al-Hassi, R.J. Rigby, S.J. Bell, A.V. Emmanuel, S.C. Knight, and et al. Characteristics of intestinal dendritic cells in inflammatory bowel diseases Gastroenterology 129 2005 50 65
38. T. Hisamatsu, T. Kanai, Y. Mikami, K. Yoneno, K. Matsuoka, and T. Hibi Immune aspects of the pathogenesis of inflammatory bowel disease Pharmacol Ther 137 2013 283 297
39. M.L. Hoivik, B. Moum, I.C. Solberg, M. Cvancarova, O. Hoie, M.H. Vatn, and et al. Health-related quality of life in patients with ulcerative colitis after a 10-year disease course: results from the IBSEN study Inflamm Bowel Dis 18 2012 1540 1549
40. M.H. Holtmann, E. Douni, M. Schutz, G. Zeller, J. Mudter, H.A. Lehr, and et al. Tumor necrosis factor-receptor 2 is up-regulated on lamina propria T cells in Crohn's disease and promotes experimental colitis in vivo Eur J Immunol 32 2002 3142 3151
41. K. Inagaki-Ohara, S. Yada, N. Takamura, M. Reaves, X. Yu, E. Liu, and et al. p53-dependent radiation-induced crypt intestinal epithelial cells apoptosis is mediated in part through TNF-TNFR1 system Oncogene 20 2001 812 818
42. K. Kanbe, J. Chiba, Y. Inoue, M. Taguchi, and A. Yabuki Predictive factors related to the efficacy of golimumab in patients with rheumatoid arthritis Clin Med Insights Arthritis Musculoskelet Disord 8 2015 25 32
43. P. Kawalec, and K.P. Malinowski Indirect health costs in ulcerative colitis and Crohn's disease: a systematic review and meta-analysis Expert Rev Pharmacoecon Outcomes Res 15 2015 253 266
44. Z. Kaymakcalan, P. Sakorafas, S. Bose, S. Scesney, L. Xiong, D.K. Hanzatian, and et al. Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor Clin Immunol 131 2009 308 316
45. S. Kirchner, E. Holler, S. Haffner, R. Andreesen, and G. Eissner Effect of different tumor necrosis factor (TNF) reactive agents on reverse signaling of membrane integrated TNF in monocytes Cytokine 28 2004 67 74
46. S. Koch, and A. Nusrat The life and death of epithelia during inflammation: lessons learned from the gut Annu Rev Pathol 7 2012 35 60
47. R.F. Leal, N. Planell, R. Kajekar, J.J. Lozano, I. Ordas, I. Dotti, and et al. Identification of inflammatory mediators in patients with Crohn's disease unresponsive to anti-TNFalpha therapy Gut 64 2015 233 242
48. Z. Li, S. Vermeire, D. Bullens, M. Ferrante, K. Van Steen, M. Noman, and et al. Restoration of Foxp3+ regulatory T-cell subsets and Foxp3- type 1 regulatory-like T cells in inflammatory bowel diseases during anti-tumor necrosis factor therapy Inflamm Bowel Dis 21 2015 2418 2428
49. H. Liu, M. Li, P. Wang, and F. Wang Blockade of hypoxia-inducible factor-1alpha by YC-1 attenuates interferon-gamma and tumor necrosis factor-alpha-induced intestinal epithelial barrier dysfunction Cytokine 56 2011 581 588
50. C. Liu, X. Xia, W. Wu, R. Wu, M. Tang, T. Chen, and et al. Anti-tumour necrosis factor therapy enhances mucosal healing through down-regulation of interleukin-21 expression and T helper type 17 cell infiltration in Crohn's disease Clin Exp Immunol 173 2013 102 111
51. T. Ljung, L.G. Axelsson, M. Herulf, J.O. Lundberg, and P.M. Hellstrom Early changes in rectal nitric oxide and mucosal inflammatory mediators in Crohn's colitis in response to infliximab treatment Aliment Pharmacol Ther 25 2007 925 932
52. E. Louis, Z. El Ghoul, S. Vermeire, S. Dall'Ozzo, P. Rutgeerts, G. Paintaud, and et al. Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease Aliment Pharmacol Ther 19 2004 511 519
53. T.T. MacDonald, P. Hutchings, M.Y. Choy, S. Murch, and A. Cooke Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine Clin Exp Immunol 81 1990 301 305
54. J. Mankertz, and J.D. Schulzke Altered permeability in inflammatory bowel disease: pathophysiology and clinical implications Curr Opin Gastroenterol 23 2007 379 383
55. B.L. McRae, A.D. Levin, M.E. Wildenberg, P.J. Koelink, P. Bousquet, I. Mikaelian, and et al. Fc receptor-mediated effector function contributes to the therapeutic response of anti-TNF monoclonal antibodies in a mouse model of inflammatory bowel disease J Crohns Colitis 10 2016 69 76
56. W.Q. Mei, H.Z. Hu, Y. Liu, Z.C. Li, and W.G. Wang Infliximab is superior to other biological agents for treatment of active ulcerative colitis: a meta-analysis World J Gastroenterol 21 2015 6044 6051
57. M.J. Meijer, M.A. Mieremet-Ooms, W. van Duijn, A.M. van der Zon, R. Hanemaaijer, J.H. Verheijen, and et al. Effect of the anti-tumor necrosis factor-alpha antibody infliximab on the ex vivo mucosal matrix metalloproteinase-proteolytic phenotype in inflammatory bowel disease Inflamm Bowel Dis 13 2007 200 210
58. Y. Merga, B.J. Campbell, and J.M. Rhodes Mucosal barrier, bacteria and inflammatory bowel disease: possibilities for therapy Dig Dis 32 2014 475 483
59. U. Meusch, M. Rossol, C. Baerwald, S. Hauschildt, and U. Wagner Outside-to-inside signaling through transmembrane tumor necrosis factor reverses pathologic interleukin-1beta production and deficient apoptosis of rheumatoid arthritis monocytes Arthritis Rheum 60 2009 2612 2621
60. H. Mitoma, T. Horiuchi, N. Hatta, H. Tsukamoto, S. Harashima, Y. Kikuchi, and et al. Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha Gastroenterology 128 2005 376 392
61. H. Mitoma, T. Horiuchi, H. Tsukamoto, Y. Tamimoto, Y. Kimoto, A. Uchino, and et al. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab Arthritis Rheum 58 2008 1248 1257
62. T. Mizutani, R. Akasaka, K. Tomita, and T. Chiba Serial changes of cytokines in Crohn's disease treated with infliximab Hepatogastroenterology 58 2011 1523 1526
63. N.A. Molodecky, I.S. Soon, D.M. Rabi, W.A. Ghali, M. Ferris, G. Chernoff, and et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review Gastroenterology 142 2012 46 54
64. R. Moroi, K. Endo, Y. Kinouchi, H. Shiga, Y. Kakuta, M. Kuroha, and et al. FCGR3A-158 polymorphism influences the biological response to infliximab in Crohn's disease through affecting the ADCC activity Immunogenetics 65 2013 265 271
65. S.H. Murch, V.A. Lamkin, M.O. Savage, J.A. Walker-Smith, and T.T. MacDonald Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease Gut 32 1991 913 917
66. M. Nagar, J. Jacob-Hirsch, H. Vernitsky, Y. Berkun, S. Ben-Horin, N. Amariglio, and et al. TNF activates a NF-kappaB-regulated cellular program in human CD45RA- regulatory T cells that modulates their suppressive function J Immunol 184 2010 3570 3581
67. A. Nesbitt, G. Fossati, M. Bergin, P. Stephens, S. Stephens, R. Foulkes, and et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents Inflamm Bowel Dis 13 2007 1323 1332
68. M.F. Neurath Cytokines in inflammatory bowel disease Nat Rev Immunol 14 2014 329 342
69. M.F. Neurath New targets for mucosal healing and therapy in inflammatory bowel diseases Mucosal Immunol 7 2014 6 19
70. O.H. Nielsen, and M.A. Ainsworth Tumor necrosis factor inhibitors for inflammatory bowel disease N Engl J Med 369 2013 754 762
71. O.H. Nielsen, P. Gionchetti, M. Ainsworth, B. Vainer, M. Campieri, N. Borregaard, and et al. Rectal dialysate and fecal concentrations of neutrophil gelatinase-associated lipocalin, interleukin-8, and tumor necrosis factor-alpha in ulcerative colitis Am J Gastroenterol 94 1999 2923 2928
72. T. Nunes, C. Bernardazzi, and H.S. de Souza Cell death and inflammatory bowel diseases: apoptosis, necrosis, and autophagy in the intestinal epithelium Biomed Res Int 2014 2014 218493
73. A. Oikonomopoulos, W.K. van Deen, and D.W. Hommes Anti-TNF antibodies in inflammatory bowel disease: do we finally know how it works? Curr Drug Targets 14 2013 1421 1432
74. T. Olsen, G. Cui, R. Goll, A. Husebekk, and J. Florholmen Infliximab therapy decreases the levels of TNF-alpha and IFN-gamma mRNA in colonic mucosa of ulcerative colitis Scand J Gastroenterol 44 2009 727 735
75. K. Papamichael, A. Gils, P. Rutgeerts, B.G. Levesque, S. Vermeire, W.J. Sandborn, and et al. Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse Inflamm Bowel Dis 21 2015 182 197
76. G. Pasut Pegylation of biological molecules and potential benefits: pharmacological properties of certolizumab pegol BioDrugs 28 Suppl. 1 2014 S15 S23
77. S.T. Peake, D. Bernardo, E.R. Mann, H.O. Al-Hassi, S.C. Knight, and A.L. Hart Mechanisms of action of anti-tumor necrosis factor alpha agents in Crohn's disease Inflamm Bowel Dis 19 2013 1546 1555
78. C. Perrier, G. de Hertogh, J. Cremer, S. Vermeire, P. Rutgeerts, G. Van Assche, and et al. Neutralization of membrane TNF, but not soluble TNF, is crucial for the treatment of experimental colitis Inflamm Bowel Dis 19 2013 246 253
79. M. Ringheanu, F. Daum, J. Markowitz, J. Levine, S. Katz, X. Lin, and et al. Effects of infliximab on apoptosis and reverse signaling of monocytes from healthy individuals and patients with Crohn's disease Inflamm Bowel Dis 10 2004 801 810
80. S. Rutella, G. Fiorino, S. Vetrano, C. Correale, A. Spinelli, N. Pagano, and et al. Infliximab therapy inhibits inflammation-induced angiogenesis in the mucosa of patients with Crohn's disease Am J Gastroenterol 106 2011 762 770
81. W.J. Sandborn, S.B. Hanauer, S. Katz, M. Safdi, D.G. Wolf, R.D. Baerg, and et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial Gastroenterology 121 2001 1088 1094
82. B. Scallon, A. Cai, N. Solowski, A. Rosenberg, X.Y. Song, D. Shealy, and et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists J Pharmacol Exp Ther 301 2002 418 426
83. B.J. Scallon, M.A. Moore, H. Trinh, D.M. Knight, and J. Ghrayeb Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions Cytokine 7 1995 251 259
84. J.D. Schulzke, C. Bojarski, S. Zeissig, F. Heller, A.H. Gitter, and M. Fromm Disrupted barrier function through epithelial cell apoptosis Ann N Y Acad Sci 1072 2006 288 299
85. D.J. Shealy, A. Cai, K. Staquet, A. Baker, E.R. Lacy, L. Johns, and et al. Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor alpha MAbs 2 2010 428 439
86. C. Shen, G.V. Assche, S. Colpaert, P. Maerten, K. Geboes, P. Rutgeerts, and et al. Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept Aliment Pharmacol Ther 21 2005 251 258
87. L. Shen, E.D. Black, E.D. Witkowski, W.I. Lencer, V. Guerriero, E.E. Schneeberger, and et al. Myosin light chain phosphorylation regulates barrier function by remodeling tight junction structure J Cell Sci 119 2006 2095 2106
88. S.M. Slevin, and L.J. Egan New insights into the mechanisms of action of anti-tumor necrosis factor-alpha monoclonal antibodies in inflammatory bowel disease Inflamm Bowel Dis 21 2015 2909 2920
89. C. Steenholdt, J. Brynskov, O.O. Thomsen, L.K. Munck, J. Fallingborg, L.A. Christensen, and et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial Gut 63 2014 919 927
90. C. Steenholdt, M.T. Frederiksen, K. Bendtzen, M.A. Ainsworth, O.O. Thomsen, and J. Brynskov Time course and clinical implications of development of antibodies against adalimumab in patients with inflammatory bowel disease J Clin Gastroenterol 2015 [Epub ahead of print]
91. A.F. Steinert, S.C. Ghivizzani, A. Rethwilm, R.S. Tuan, C.H. Evans, and U. Noth Major biological obstacles for persistent cell-based regeneration of articular cartilage Arthritis Res Ther 9 2007 213
92. P. Suenaert, V. Bulteel, L. Lemmens, M. Noman, B. Geypens, G. Van Assche, and et al. Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease Am J Gastroenterol 97 2002 2000 2004
93. Y. Suzuki, T. Matsui, H. Ito, T. Ashida, S. Nakamura, S. Motoya, and et al. Circulating interleukin 6 and albumin, and infliximab levels are good predictors of recovering efficacy after dose escalation infliximab therapy in patients with loss of response to treatment for Crohn's disease: a prospective clinical trial Inflamm Bowel Dis 21 2015 2114 2122
94. B. Szalay, B. Vasarhelyi, A. Cseh, T. Tulassay, M. Deak, L. Kovacs, and et al. The impact of conventional DMARD and biological therapies on CD4+ cell subsets in rheumatoid arthritis: a follow-up study Clin Rheumatol 33 2014 175 185
95. P.C. Taylor Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases Curr Opin Pharmacol 10 2010 308 315
96. T. ten Hove, C. van Montfrans, M.P. Peppelenbosch, and S.J. van Deventer Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease Gut 50 2002 206 211
97. K. Thorlund, E. Druyts, K. Toor, and E.J. Mills Comparative efficacy of golimumab, infliximab, and adalimumab for moderately to severely active ulcerative colitis: a network meta-analysis accounting for differences in trial designs Expert Rev Gastroenterol Hepatol 9 2015 693 700
98. G. Toedter, K. Li, C. Marano, K. Ma, S. Sague, C.C. Huang, and et al. Gene expression profiling and response signatures associated with differential responses to infliximab treatment in ulcerative colitis Am J Gastroenterol 106 2011 1272 1280
99. G. Toedter, K. Li, S. Sague, K. Ma, C. Marano, M. Macoritto, and et al. Genes associated with intestinal permeability in ulcerative colitis: changes in expression following infliximab therapy Inflamm Bowel Dis 18 2012 1399 1410
100. D. Tracey, L. Klareskog, E.H. Sasso, J.G. Salfeld, and P.P. Tak Tumor necrosis factor antagonist mechanisms of action: a comprehensive review Pharmacol Ther 117 2008 244 279
101. G.S. Tun, and A.J. Lobo Evaluation of pharmacokinetics and pharmacodynamics and clinical efficacy of certolizumab pegol for Crohn's disease Expert Opin Drug Metab Toxicol 11 2015 317 327
102. N. Ueda, H. Tsukamoto, H. Mitoma, M. Ayano, A. Tanaka, S. Ohta, and et al. The cytotoxic effects of certolizumab pegol and golimumab mediated by transmembrane tumor necrosis factor alpha Inflamm Bowel Dis 19 2013 1224 1231
103. B. Ungar, I. Levy, Y. Yavne, M. Yavzori, O. Picard, E. Fudim, and et al. Optimizing anti-TNFalpha therapy: serum levels of infliximab and adalimumab associate with mucosal healing in patients with inflammatory bowel diseases Clin Gastroenterol Hepatol 2015 [Epub ahead of print]
104. X. Valencia, G. Stephens, R. Goldbach-Mansky, M. Wilson, E.M. Shevach, and P.E. Lipsky TNF downmodulates the function of human CD4 + CD25hi T-regulatory cells Blood 108 2006 253 261
105. J.M. Van den Brande, H. Braat, G.R. van den Brink, H.H. Versteeg, C.A. Bauer, I. Hoedemaeker, and et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease Gastroenterology 124 2003 1774 1785
106. J.M. Van den Brande, T.C. Koehler, Z. Zelinkova, R.J. Bennink, A.A. te Velde, F.J. ten Cate, and et al. Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease Gut 56 2007 509 517
107. M. van der Have, K.S. van der Aalst, A.A. Kaptein, M. Leenders, P.D. Siersema, B. Oldenburg, and et al. Determinants of health-related quality of life in Crohn's disease: a systematic review and meta-analysis J Crohns Colitis 8 2014 93 106
108. N. Vande Casteele, M. Ferrante, G. Van Assche, V. Ballet, G. Compernolle, K. Van Steen, and et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease Gastroenterology 148 2015 1320 1329
109. C. Veltkamp, M. Anstaett, K. Wahl, S. Moller, S. Gangl, O. Bachmann, and et al. Apoptosis of regulatory T lymphocytes is increased in chronic inflammatory bowel disease and reversed by anti-TNFalpha treatment Gut 60 2011 1345 1353
110. F.B. Vincent, E.F. Morand, K. Murphy, F. Mackay, X. Mariette, and C. Marcelli Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective Ann Rheum Dis 72 2013 165 178
111. A.C. Vos, M.E. Wildenberg, I. Arijs, M. Duijvestein, A.P. Verhaar, G. de Hertogh, and et al. Regulatory macrophages induced by infliximab are involved in healing in vivo and in vitro Inflamm Bowel Dis 18 2012 401 408
112. A.C. Vos, M.E. Wildenberg, M. Duijvestein, A.P. Verhaar, G.R. van den Brink, and D.W. Hommes Anti-tumor necrosis factor-alpha antibodies induce regulatory macrophages in an Fc region-dependent manner Gastroenterology 140 2011 221 230
113. K.A. Wojtal, G. Rogler, M. Scharl, L. Biedermann, P. Frei, M. Fried, and et al. Fc gamma receptor CD64 modulates the inhibitory activity of infliximab PLoS One 7 2012 e43361
114. A.J. Yarur, A. Jain, D.A. Sussman, J.S. Barkin, M.A. Quintero, F. Princen, and et al. The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study Gut 65 2016 249 255
115. S. Zeissig, C. Bojarski, N. Buergel, J. Mankertz, M. Zeitz, M. Fromm, and et al. Downregulation of epithelial apoptosis and barrier repair in active Crohn's disease by tumour necrosis factor alpha antibody treatment Gut 53 2004 1295 1302
116. X. Zheng, K. Tsuchiya, R. Okamoto, M. Iwasaki, Y. Kano, N. Sakamoto, and et al. Suppression of hath1 gene expression directly regulated by hes1 via notch signaling is associated with goblet cell depletion in ulcerative colitis Inflamm Bowel Dis 17 2011 2251 2260